James Robinson is the Chief Executive Officer of Urovant Sciences, Inc., since March 23, 2020. He served as a member of our board of directors since March 2019. Mr. Robinson is a proven leader in the biopharmaceutical and healthcare industries, having successfully led multiple global businesses, operations and commercial ventures in multiple corporations over the past 28 years.

Most recently, Mr. Robinson held the position of President and Chief Operating Officer at Paragon Biosciences where he oversaw Paragon’s operations. Previously, Mr. Robinson served as the President and Chief Operating Officer of Alkermes, where he was responsible for global commercial, new product planning, corporate planning, manufacturing, quality, human resources and business development functions. Prior to Alkermes, Mr. Robinson spent over twelve years at Astellas U.S. – most recently as President, Americas Operations, where his responsibilities included all aspects of operations for North and South America. Prior to that, he was President of Astellas Pharma US, where he was responsible for leading the U.S. commercial organization. Prior to Astellas, Mr. Robinson spent thirteen years at Schering-Plough Pharmaceuticals, where his last role was Vice President, Hepatitis Sales and Managed Care.

In addition to his membership on the Urovant Board of Directors, Mr. Robinson also was named to the Board of Directors of Applied Genetic Technologies Corporation in December 2021. He also currently serves as an advisor to BridgeBio. Previously, Mr. Robinson served on the Board of Directors for Neos Therapeutics prior to its acquisition by Aytu Biopharma. He also previously served on the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA) and served as Chairman of PhRMA’s State Committee. He is a founding member of MATTER. Mr. Robinson received a Bachelor of Science degree from DePaul University.